Adjunctive treatment with high frequency repetitive transcranial magnetic stimulation for the behavioral and psychological symptoms of patients with Alzheimer's disease: a randomized, double-blind, sham-controlled study
Introduction
In China the prevalence of senile dementia in persons 60 years of age and older is reported to be 4.8%. [1] Dramatic improvements in health in China and the one child per family policy have resulted in a rapid increase in the proportion of the population that is elderly, and, thus, a similarly dramatic increase in the number of individuals with dementia. As the most common type of senile dementia, Alzheimer's Disease (AD) has become a serious public health problem. AD is a primary degenerative cerebral disease of unknown etiology with a predominant clinical picture of cognitive impairment and different degrees of behavioral and psychological symptoms of dementia (BPSD). The incidence of BPSD during different stages of AD is 70-90%, [2] [3] and primarily consists of hallucinations, delusions, agitation, and behavioral disorders. Moreover, BPSD can exacerbate the cognitive and social dysfunction of AD, leading to decreased quality of life for both patients and caregivers, more frequent hospitalizations, and a higher burden of illness.
Currently, the management of BPSD usually involves the use of atypical antipsychotic medications at 1/3-1/2 the dosage recommended for primary psychosis. [4] [5] However, over the last decade several studies have reported increased rates of severe adverse reactions in AD patients treated with antipsychotic medications, primarily cardiovascular events and respiratory infections. [6] This has resulted in the increased use of other, non-pharmacological methods for managing BPSD, such as physical therapy. [7] Another alternative approach to BPSD might be the use of repetitive transcranial magnetic stimulation (rTMS), a painless, non-invasive treatment that has been shown to be safe and effective for various neurological and psychiatric conditions. [8] [9] rTMS has a beneficial effect in the treatment of different mental disorders associated with the persistence of auditory hallucinations, agitation, anxiety, and depression; and it is associated with improved cognitive functioning. [10] [11] [12] Recent studies have shown that rTMS can delay the progression and improve cognitive function in AD without inducing any serious adverse events. [13] [14] [15] [16] But there have been few studies that assess the effects of rTMS on BPSD in persons with AD. The purpose of this study is to assess whether or not rTMS used as an adjunctive treatment to low-dose risperidone can improve the BPSD symptoms and cognitive functioning of individuals with AD.
Participants and methods

Participants
The recruitment and research procedures are shown in [17] b) 60-80 years of age; c) minimum of 5 years of education; d) total score on Mini-Mental State Examination(MMSE) [18] of less than 24; e) total score on Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) [19] of greater than 8; e) no history of epilepsy, stroke, or major head trauma; f) no severe physical illness or implants which could limit the use of rTMS; and g) had not taken antipsychotic medications or other drugs affecting mental activity in the previous month.
Fifty-four patients who met these inclusion criteria were randomly assigned (using a standard table of random numbers) before the commencement of the trial to either the intervention group or the control group. As shown in Table 1 , there were no statistically significant differences between the two groups at baseline in age, gender distribution, educational level, course of the disease, or MMSE score.
The protocol for this project was approved by the Ethics Committee of the Wuxi Mental Health Center. Informed consents were obtained from all participants.
Intervention
This was a double-blind, randomized, sham-controlled study in which the rTMS therapist (who was not involved in the clinical assessment of the patients) used a random number table to assign subjects to either the real rTMS or the sham rTMS condition. In addition to conventional treatment with risperidone 1 mg per day, all patients were administered real or sham rTMS treatments for a total of 20 sessions, 5 days a week for 4 consecutive weeks. Other antipsychotic drugs were not used during the treatment.
A MagproR30 rTMS machine (with the figure-eight electromagnet) manufactured by Medtronic (a Danish company) was employed in the study. Patients lay down on a treatment table during the rTMS procedure. The stimulation position was over the left dorsolateral prefrontal cortex (DLPFC). [11] The stimulus intensity was 80% of the motor threshold (MT) and the frequency was 20 Hz for all patients. The total number of pulses was 1200 for a single treatment session. In the control group, the coils were turned 180 degrees so the magnetic field penetrating the brain was so weak that it was considered a sham condition; other settings were the same as those used in the intervention group.
Assessments
The primary outcome measure was the change in scores of the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD). [19] A secondary outcome was the change in scores of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADASCog).
[20] BEHAVE-AD scores and ADAS-Cog scores were rated at baseline and after 4 weeks of treatment. The ratings were conducted by two attending-physician level psychiatrists who had been trained in the use of the scales and who were blind to the treatment status of the patients; their inter-rater reliability based on the simultaneous assessment of six patients was good (ICC=0.79-0.86). The percent reduction from baseline in the BEHAVE-AD total score was used to assess the effectiveness of treatment: based on cutoff scores used in a previous study, [21] those with ≥60% reduction were classified as 'effectively treated'; those with 30-59% reduction were classified as 'improved'; and those with <30% reduction were classified as 'not improved'.
BEHAVE-AD is a 25-item scale that assesses seven aspects of behavioral pathology including delusions and paranoid ideation, hallucinations, activity disturbances, aggressiveness, diurnal rhythm disturbances, affective disturbances, and anxieties and phobias; the range in scores is from 0 to 75, with lower scores representing better functioning. ADAS-Cog is a 12-item scale that assesses four aspects of cognitive functioning including memory, language, constructional praxis, and attention; the range in the total score is from 0 to 75, with lower scores representing better functioning.
Vital signs and adverse events were recorded at the time of each rTMS treatment. Routine blood tests, urine 
Results
As shown in Figure 1 , one patient dropped out of each group, so the final analysis was based on data from the 26 subjects in each group that completed the 4-week treatment.
As shown in Table 2 , there were no significant differences at baseline between groups in the total • 284 • BEHAVE-AD score or in any of the seven BEHAVE-AD subscale scores. After 4 weeks of treatment, the total BEHAVE-AD score decreased (i.e., improved) significantly in both groups, but the decrease in the subscale scores was statistically significant for only six of the subscale scores in the intervention group and for only four of the subscale scores in the control group. The hallucination subscale score did not decrease significantly in either group. After controlling for baseline values using a repeated measures ANOVA, the improvement in the total BEHAVE-AD score after 4 weeks of treatment was significantly greater in the intervention group than in the control group. The improvement was also greater in the intervention group for five of the seven BEHAVE-AD subscale scores: activity disturbances, diurnal rhythm disturbances, aggressiveness, affective disturbances, and anxiety and fear.
Based on considering a 60% decrease from baseline in the total BEHAVE-AD score as the cutoff for 'effective treatment', 30-59% for 'improvement', and <30% for 'no improvement', 3 patients in the intervention group (11.5%) were effectively treated, 16 (61.5%) were improved, and 7 (26.9%) were not improved after treatment; in the control group 1 (3.8%) patient was effectively treated, 10 (38.5%) were improved, and 15 (41.7%) were not improved. That is, 73.1% (19/26) of the patients in the rTMS group showed improvement in their behavioral and psychological symptoms compared to only 42.3% (11/26) in the control group (X 2 =5.04, p=0.025).
As shown in Table 3 , there were no significant differences in the ADAS-Cog total scores or in any of the four subscale scores between groups at baseline. After 4 weeks of treatment, the ADAS-Cog total scores dropped (i.e., improved) significantly in both groups, and the subscale scores dropped significantly in all four subscales in the intervention group and in two of the four subscales scores in the control group (the memory and attention subscales). After controlling for baseline values using a repeated measures ANOVA, the improvement in the total ADAS-Cog score after 4 weeks of treatment was significantly greater in the intervention group than in the control group. The improvement was also greater in the intervention group for all four ADASCog subscale scores: memory, language, constructional praxis, and attention.
Combining results for all 52 participants who completed the study, the correlation of the BEHAVE-AD total score and the ADAS-Cog total score was nonsignificant, both at baseline (r s =0.11, p=0.459) and after treatment (r s =0.02, p=0.869). However, the magnitude of the change in the total scores of the two scales over the course of treatment was statistically significant (r s = 0.33, p=0.015).
During rTMS treatments, no patients experienced seizures or epilepsy-like symptoms. There were no The most common adverse reactions in both groups reported on the TESS were mild extrapyramidal reactions (4 cases in the intervention group and 2 cases in the control group) and transient headache (4 cases in the intervention group and 5 cases in the control group). These side effects were mild and well tolerated. Overall, 30.8% (8/26) of the participants in the intervention group experienced an adverse event during the study while 26.9% (7/26) in the control group experienced an adverse event (X 2 =0.09, p=0.760).
Discussion
Main findings
This study used a randomized, double-blind design to compare the efficacy and safety of high frequency rTMS combined with low-dose risperidone to that of risperidone treatment alone for the treatment of BPSD in patients with AD. We found that 4 weeks of high frequency rTMS to the left DLPFC is an effective adjunctive treatment method for the treatment of BPSD in patients with AD. A much higher proportion of patients receiving rTMS than patients receiving sham rTMS experienced a 30% or greater drop in the overall BEHAVE-AD score (73.1% vs. 42.3%), indicating that the behavioral and psychological symptoms had substantially improved. These findings are similar to those of other studies. Peng and colleagues [22] reported that TMS is more effective than drug therapy for BPSD, including sleep quality, anxiety and depression, aggression, and agitation. Another study in China by Wu and colleagues [23] also reported that rTMS improved BPSD, but the study did not include a sham rTMS comparison group. The efficacy of risperidone treatment alone reported in this study was similar to that reported by Onor and colleagues, [24] which found that low-dose risperidone was associated with reductions in agitation, aggression, irritability, delusions, and sleep disorders.
We found no significant improvement in either group in the hallucination subscale score of the BEHAVE-AD after 4 weeks of treatment. Becker and colleagues [25] regarded the occurrence of hallucinations as a marker of the severity of AD psychopathology; if true, this could explain the apparent insensitivity of hallucinations to treatment. On the other hand, a recent study [26] that reported the effectiveness of rTMS as an adjunctive treatment for auditory hallucinations used low-frequency stimulation, while our study used high-frequency rTMS. Future studies should assess the effectiveness of treating AD with low-frequency rTMS.
We also found that the cognitive functioning of the high frequency rTMS group improved significantly more than in the sham rTMS group that only received the low-dose risperidone. This finding is similar to that of a study by Ahmed and colleagues [15] which reported a significant improvement in MMSE after five daily sessions of high frequency rTMS (20Hz) over the DLPFC, an improvement that was maintained for three months after the end of rTMS treatments. Other studies have found that rTMS over the DLPFC has a good treatment effect on cognitive impairment in both mild AD and in moderate-to-severe AD. [27] [28] A study by Bentwich and colleagues [29] also showed a significant effect of rTMS (20 Hz) over the DLPFC in improving the scores of an auditory sentence comprehension test among patients with AD.
In this study there was no correlation between total BEHAVE-AD and ADAS-Cog scores among the 52 AD patients who completed the study, but there was a modest correlation (r s =0.33, p=0.015) between the magnitude of the improvement in cognitive symptoms (assessed by ADAS-Cog score) and the magnitude of improvement in behavioral and psychological symptoms (assessed by BEHAVE-AD) over the 4 weeks of treatment. Hollingworth and colleagues [30] consider BPSD in patients with AD a secondary cluster of symptoms directly resulting from the primary cognitive impairment, but Shinno and colleagues [31] consider BPSD and cognitive impairment two separate clusters of pathological symptoms. Our results suggest that BPSD and cognitive impairment are different, but related, pathological states.
This study, which administered high-frequency rTMS to 26 patients five days a week for four consecutive weeks, confirms previous results about the relative safety of this treatment. No seizures or other severe adverse effects were observed during the 4 weeks of treatment and there were no significant differences in the prevalence or severity of adverse reactions between the active and sham rTMS groups.
Limitations
There are several potential limitations to these results. The study has a relatively small sample size so some of the negative results, such as the failure to find significant differences for some of the subscale scores, may be due to Type II errors. We only assessed the treatment outcome at the end of the 4 weeks of rTMS treatment sessions. Follow-up studies are needed to determine a) how soon the treatment effect of rTMS manifests, b) how long the treatment effect persists after termination of the rTMS intervention, c) whether or not the effect will be greater if the rTMS is continued longer, d) whether or not rTMS can replace medication in individuals who are not tolerant to medication, and e) the appropriate interval and intensity of 'booster sessions' with rTMS to sustain the positive effect. We only used a single frequency (20Hz) and a single location (the DLPFC) for rTMS; additional studies will be needed to test the effect when rTMS is used at different frequencies and applied at different locations. Ultimately the goal will be to identify the parameters that can be used to tailor rTMS treatments to specific patients.
Importance
Our study found that high-frequency rTMS used as an adjunctive treatment with low-dose risperidone can Anxiety Disorder, a common mental illness that is often chronic, has recently received increased attention by psychiatric researchers in China. The largest community-based epidemiological survey of mental disorders yet conducted in China (published in 2009) reported that the one-month prevalence of anxiety disorder was 5.6% (95% confidence interval, 5.0%-6.3%), but 93.9% of these individuals had never sought treatment for the condition; 3.2% had seen a non-specialist doctor and 2.9% had seen a psychiatrist. Promoting research that will help narrow this huge treatment gap is one of the key goals of the 8 th National Anxiety Conference that will be held May 6-7, 2016 in Wuhan, Hubei Province, China. Conference theme: Treating anxiety to improve quality of life Content: a) lectures on recent progress in the treatment and research of anxiety; b) symposium about the diagnosis, treatment, and comorbidity (both physical and mental) of anxiety; c) discussion of research articles about anxiety; d) face-to-face discussion with experts about relevant and timely topics.
